{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:12:17Z","timestamp":1776852737033,"version":"3.51.2"},"reference-count":36,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDB\/04046\/2020"],"award-info":[{"award-number":["UIDB\/04046\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e Tecnologia","doi-asserted-by":"publisher","award":["UIDP\/04046\/2020"],"award-info":[{"award-number":["UIDP\/04046\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000292","name":"Cystic Fibrosis Trust","doi-asserted-by":"publisher","award":["SRC 013"],"award-info":[{"award-number":["SRC 013"]}],"id":[{"id":"10.13039\/501100000292","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>SLC26A9, a constitutively active Cl\u2212 transporter, has gained interest over the past years as a relevant disease modifier in several respiratory disorders including Cystic Fibrosis (CF), asthma, and non-CF bronchiectasis. SLC26A9 contributes to epithelial Cl\u2212 secretion, thus preventing mucus obstruction under inflammatory conditions. Additionally, SLC26A9 was identified as a CF gene modifier, and its polymorphisms were shown to correlate with the response to drugs modulating CFTR, the defective protein in CF. Here, we aimed to investigate the relationship between SLC26A9 and CFTR, and its role in CF pathogenesis. Our data show that SLC26A9 expression contributes to enhanced CFTR expression and function. While knocking-down SLC26A9 in human bronchial cells leads to lower wt- and F508del-CFTR expression, function, and response to CFTR correctors, the opposite occurs upon its overexpression, highlighting SLC26A9 relevance for CF. Accordingly, F508del-CFTR rescue by the most efficient correctors available is further enhanced by increasing SLC26A9 expression. Interestingly, SLC26A9 overexpression does not increase the PM expression of non-F508del CFTR traffic mutants, namely those unresponsive to corrector drugs. Altogether, our data indicate that SLC26A9 stabilizes CFTR at the ER level and that the efficacy of CFTR modulator drugs may be further enhanced by increasing its expression.<\/jats:p>","DOI":"10.3390\/ijms222313064","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T21:19:08Z","timestamp":1638479948000},"page":"13064","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-269X","authenticated-orcid":false,"given":"Madalena C.","family":"Pinto","sequence":"first","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]},{"given":"Margarida C.","family":"Quaresma","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8062-5558","authenticated-orcid":false,"given":"Iris A. L.","family":"Silva","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]},{"given":"Violeta","family":"Railean","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7554-9802","authenticated-orcid":false,"given":"Sofia S.","family":"Ramalho","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0828-8630","authenticated-orcid":false,"given":"Margarida D.","family":"Amaral","sequence":"additional","affiliation":[{"name":"BioISI\u2014Biosystems & Integrative Sciences Institute, Faculty of Sciences, University of Lisboa, Campo Grande, C8, 1749-016 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/joim.12314","article-title":"Novel personalized therapies for cystic fibrosis: Treating the basic defect in all patients","volume":"277","author":"Amaral","year":"2015","journal-title":"J. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.2475911","article-title":"Identification the cystic fibrosis gene: Cloning and characterization of complementary DNA","volume":"245","author":"Riordan","year":"1989","journal-title":"Science"},{"key":"ref_3","first-page":"38","article-title":"CFTR and bicarbonate secretion by epithelial cells","volume":"18","author":"Hug","year":"2003","journal-title":"News Physiol. Sci."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrg3849","article-title":"Cystic fibrosis genetics: From molecular understanding to clinical application","volume":"16","author":"Cutting","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1159\/000029497","article-title":"Genotype and phenotype in cystic fibrosis","volume":"67","author":"Zielenski","year":"2000","journal-title":"Respiration"},{"key":"ref_6","first-page":"1","article-title":"CFTR modulators: Shedding light on precision medicine for cystic fibrosis","volume":"7","year":"2016","journal-title":"Front. Pharmacol."},{"key":"ref_7","unstructured":"(2021, October 07). CFTR2 Variant List History. Available online: https:\/\/cftr2.org\/mutations_history."},{"key":"ref_8","unstructured":"(2021, October 07). Cystic Fibrosis Mutation Database. Available online: http:\/\/www.genet.sickkids.on.ca\/cftr\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pharmthera.2014.06.005","article-title":"New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls","volume":"145","author":"Bell","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"Amaral","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1007\/s00424-003-1090-3","article-title":"The SLC26 gene family of multifunctional anion exchangers","volume":"447","author":"Mount","year":"2004","journal-title":"Pflug. Arch. Eur. J. Physiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1085\/jgp.200810097","article-title":"SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia","volume":"133","author":"Bertrand","year":"2009","journal-title":"J. Gen. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1152\/physiol.00037.2007","article-title":"The solute carrier 26 family of proteins in epithelial ion transport","volume":"23","author":"Dorwart","year":"2008","journal-title":"Physiology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3389\/fphar.2018.01112","article-title":"Role of the SLC26A9 chloride channel as disease modifier and potential therapeutic target in cystic fibrosis","volume":"9","author":"Mall","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_17","first-page":"4590","article-title":"Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics","volume":"25","author":"Strug","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3389\/fphar.2018.00828","article-title":"SLC26A9 gene is associated with lung function response to ivacaftor in patients with cystic fibrosis","volume":"9","author":"Corvol","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbadis.2019.01.029","article-title":"Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del\/F508del Cystic Fibrosis patients","volume":"1865","author":"Kmit","year":"2019","journal-title":"Biochim. Biophys. Acta\u2014Mol. Basis. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/ng.2221","article-title":"Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis","volume":"44","author":"Sun","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00439-013-1363-7","article-title":"Unraveling the complex genetic model for cystic fibrosis: Pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities","volume":"133","author":"Li","year":"2014","journal-title":"Hum. Genet."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jpeds.2015.01.044","article-title":"Variants in solute carrier SLC26A9 modify prenatal exocrine pancreatic damage in cystic fibrosis","volume":"166","author":"Miller","year":"2015","journal-title":"J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1172\/JCI129833","article-title":"Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis","volume":"130","author":"Lam","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1172\/JCI60429","article-title":"SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation","volume":"122","author":"Anagnostopoulou","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/jcp.22967","article-title":"Differential contribution of SLC26A9 to Cl\u2212 conductance in polarized and non-polarized epithelial cells","volume":"227","author":"Ousingsawat","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/jcp.22328","article-title":"SLC26A9 stimulates CFTR expression and function in human bronchial cell lines","volume":"226","author":"Avella","year":"2011","journal-title":"J. Cell. Physiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"18269","DOI":"10.1074\/jbc.RA119.010192","article-title":"The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR","volume":"294","author":"Sato","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"L12","DOI":"10.1152\/ajplung.00178.2016","article-title":"The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9","volume":"312","author":"Bertrand","year":"2017","journal-title":"Am. J. Physiol.\u2014Lung. Cell. Mol. Physiol."},{"key":"ref_29","first-page":"4396","article-title":"CFTR interacts with ZO-1 to regulate tight junction assembly and epithelial differentiation through the ZONAB pathway","volume":"127","author":"Ruan","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00441-013-1734-3","article-title":"Disrupted tight junctions in the small intestine of cystic fibrosis mice","volume":"355","year":"2014","journal-title":"Cell Tissue Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jcf.2020.07.015","article-title":"Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants","volume":"20","author":"Laselva","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41419-020-03119-z","article-title":"Mutant CFTR Drives TWIST1 mediated epithelial\u2013mesenchymal transition","volume":"11","author":"Quaresma","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1113\/jphysiol.2009.182246","article-title":"Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers","volume":"588","author":"LeSimple","year":"2010","journal-title":"J. Physiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2002774","DOI":"10.1183\/13993003.02774-2020","article-title":"Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator","volume":"57","author":"Laselva","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_35","unstructured":"Amatngalim, G.D., Rodenburg, L.W., Aalbers, B.L., Raeven, H.H.M., Aarts, E.M., Silva, I.A.L., Nijenhuis, W., Vrendenbarg, S., Kruisselbrink, E., and Brunsveld, J.E. (2021). CFTR modulator response measurements in subjects with cystic fibrosis using 2D differentiated nasal epithelia converted into spheroids. bioRxiv."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: An open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat. Methods"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/13064\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:39:00Z","timestamp":1760168340000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/23\/13064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":36,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["ijms222313064"],"URL":"https:\/\/doi.org\/10.3390\/ijms222313064","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}